



Gram-Negative Multidrug Resistant Pathogen and Its Treatment

Guest Editor:

Dr. Ramón Pérez-Tanoira

1. Department of Microbiology,
Hospital Universitario Príncipe de
Asturias, 28805 Madrid, Spain
2. Department of Biomedicine
and Biotechnology, Universidad
de Alcalá, 28801 Alcalá de
Henares, Spain

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editor

During the COVID-19 pandemic, the emergence of extremely resistant microorganisms and an increase in the incidence of carbapenem resistance were documented, possibly related to the increased use of broad-spectrum antibiotics in patients with COVID-19. The rapid global spread of bacteria that have acquired new resistance mechanisms is one of the greatest threats to global health today, causing infections that are impossible to treat.

The spread of carbapenemase-producing Enterobacteriaceae (CFE), multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of *Pseudomonas aeruginosa* are a global health problem due to their ease of transmission and difficulty of treatment. Nosocomial infections associated with these Gram-negative bacteria have high morbidity and mortality rates, usually occurring in immunocompromised patients and those with multiple comorbidities and undergoing diagnostic-therapeutic procedures and prolonged hospital stays. These bacteria have an outstanding capacity to be selected and to propagate antimicrobial resistance in vivo. For all these reasons, the development of new antibiotics is a top priority.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi